In short
Oditrasertib, also known as SAR443820, is a promising drug currently being studied in clinical trials for its potential benefits in treating multiple sclerosis (MS). This article explores the ongoing research on Oditrasertib, focusing on its effects on serum neurofilament levels and other important aspects of MS progression. The trial aims to assess the drug's efficacy, safety, and long-term effects in patients with various forms of MS.
At a glance
- Drug Name
- Oditrasertib (SAR443820)
- Study Type
- Phase 2 double-blind, randomized, placebo-controlled study
- Main Objective
- Assess effect on serum neurofilament levels in MS patients
- Study Duration
- Part A: 48 weeks, Part B: up to 96 weeks (long-term extension)
- Participant Criteria
- 18-60 years old, diagnosed with RRMS, SPMS, or PPMS, EDSS score 2-6
- Key Outcomes Measured
- sNfL levels, brain lesions, disability progression, brain volume loss, relapses
- Drug Administration
- Oral, film-coated tablet, max daily dose 20 mg
- Safety Assessments
- Adverse events, laboratory tests, ECG, vital signs
What is ODITRASERTIB?
ODITRASERTIB, also known as SAR443820 or DNL-788, is a new medication being studied for the treatment of multiple sclerosis (MS). Multiple sclerosis is a chronic disease that affects the central nervous system, including the brain, spinal cord, and optic nerves.
This medication is currently undergoing clinical trials to evaluate its effectiveness and safety in treating various forms of MS, including relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS).
How ODITRASERTIB Works
ODITRASERTIB is classified as a small molecule drug. While the exact mechanism of action is not fully described in the provided information, small molecule drugs typically work by targeting specific proteins or pathways in the body that are involved in the disease process.
In the case of multiple sclerosis, ODITRASERTIB may help reduce inflammation and protect nerve cells from damage, which are key factors in the progression of the disease.
Potential Benefits of ODITRASERTIB
The ongoing clinical trial aims to assess several potential benefits of ODITRASERTIB for MS patients, including:
- Reduction in serum neurofilament levels (sNfL), which are markers of nerve cell damage
- Decrease in the number of new or enlarging brain lesions detected by MRI
- Slowing down of disability progression
- Improvement in physical function and quality of life
- Reduction in brain volume loss
Ongoing Research
ODITRASERTIB is currently being studied in a Phase 2 clinical trial. This trial is divided into two parts:
- Part A: A 48-week double-blind, randomized, placebo-controlled study to evaluate the effect of ODITRASERTIB on serum neurofilament levels and other measures of disease activity.
- Part B: A long-term extension period to assess the durability of the treatment effects and long-term safety.
The study will use various methods to measure the effectiveness of ODITRASERTIB, including:
- MRI scans: To detect changes in brain lesions and brain volume
- Clinical assessments: Such as the Expanded Disability Status Scale (EDSS), 9-Hole Peg Test, and timed 25-foot walk test
- Patient-reported outcomes: To evaluate the impact on quality of life
Who Can Participate in the Study?
The study is open to adults aged 18 to 60 with a diagnosis of RRMS, SPMS, or PPMS. Some key eligibility criteria include:
- An EDSS score between 2 and 6
- Stable on allowed disease-modifying therapies or untreated
- No recent relapses or significant cognitive impairment
It's important to note that there are additional inclusion and exclusion criteria that a healthcare provider would review with potential participants.
Safety Considerations
As with any new medication, safety is a crucial aspect of the ODITRASERTIB clinical trial. The study will closely monitor for any side effects or adverse events. Some safety measures include:
- Regular monitoring of laboratory tests
- Electrocardiogram (ECG) assessments
- Tracking of adverse events and serious adverse events
It's important to remember that ODITRASERTIB is still an investigational drug, and its full safety profile is not yet known. Patients considering participation in the clinical trial should discuss the potential risks and benefits with their healthcare provider.